Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;31(1):55-61.
doi: 10.53854/liim-3101-8. eCollection 2022.

Risk factors and outcomes of fungal superinfections in patients with severe COVID-19: an observational study from Pisa academic hospital

Giusy Tiseo  1 , Valentina Galfo  1 , Sara Occhineri  1 , Arianna Forniti  1 , Claudio Caroselli  1 , Marco Falcone  1 , Francesco Menichetti  1
Affiliations

Risk factors and outcomes of fungal superinfections in patients with severe COVID-19: an observational study from Pisa academic hospital

Giusy Tiseo et al. Infez Med. .

Abstract

Background: Superinfections acquired during the hospital course represent common complications in COVID-19 patients. Several studies reported an increasing incidence of COVID-19 associated pulmonary aspergillosis (CAPA) and candidaemia. The aim of this study is to describe fungal superinfections in a large cohort of hospitalized patients with COVID-19 and identify factors independently associated with the risk of fungal superinfections.

Methods: Observational study including patients with COVID-19 admitted to the tertiary-care, University Hospital of Pisa, Italy from April 2020 to May 2021. Patients with pneumonia and laboratory confirmed SARS-CoV-2 infection with a RT-PCR test on a nasopharyngeal swab, were eligible for the study. Patients who died within 24 hours from admission and those with missing data were excluded. Data about fungal superinfections were collected. To identify factors independently associated with the development of fungal superinfections, a multivariate regression analysis was performed.

Results: Among 983 patients with COVID-19, 52 (5.3%) fungal superinfections were detected. Fungal superinfections included: 24/52 (46%) CAPA, 27/52 (51.9%) episodes of candidaemia and 1 case of pulmonary pneumocystosis in a haematological patient. All patients with CAPA were cared for in intensive care unit (ICU). The majority of patients received liposomal amphotericin B as antifungal treatment (83.3%). In-hospital mortality was 41.7%. Among 27 episodes of candidaemia, 16 (59.3%) occurred in ICU while 11 (40.7%) in medical wards. In-hospital mortality was 14.8%. Overall, patients with fungal superinfections had a median age of 73 (IQRs 59-77) years and a median length of ICU stay of 40 (17-50) days. In-hospital mortality among all patients with superinfections was 28.8%. On multivariable analysis, ICU stay (OR 17.63, 95% CI 8.3-37.41, p<0.001), high-dose steroids (OR 13.48, 95% CI 6.68-27.26, p<0.001), and diabetes mellitus (OR 2.14, 95% CI 1.09-4.17, p=0.026) were factors independently associated with the risk of developing a fungal superinfection.

Conclusions: Fungal superinfections may complicate the hospital course of COVID-19 patients, especially of those admitted to ICU. Surveillance with detection of galactomannan on bronchoalveolar lavage in patients with clinical deterioration should be performed. A rational use of steroids is essential to avoid the risk of developing a fungal superinfection.

Keywords: COVID-19; Fungal infections; SARS-CoV-2; candidemia; pulmonary aspergillosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of fungal superinfections in COVID-19 patients hospitalized in all type of wards and in ICU.
See this image and copyright information in PMC

Similar articles

  • Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study.
    Falcone M, Tiseo G, Giordano C, Leonildi A, Menichini M, Vecchione A, Pistello M, Guarracino F, Ghiadoni L, Forfori F, Barnini S, Menichetti F; Pisa COVID-19 Study Group. Falcone M, et al. J Antimicrob Chemother. 2021 Mar 12;76(4):1078-1084. doi: 10.1093/jac/dkaa530. J Antimicrob Chemother. 2021. PMID: 33374002 Free PMC article.
  • COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave.
    Bretagne S, Sitbon K, Botterel F, Dellière S, Letscher-Bru V, Chouaki T, Bellanger AP, Bonnal C, Fekkar A, Persat F, Costa D, Bourgeois N, Dalle F, Lussac-Sorton F, Paugam A, Cassaing S, Hasseine L, Huguenin A, Guennouni N, Mazars E, Le Gal S, Sasso M, Brun S, Cadot L, Cassagne C, Cateau E, Gangneux JP, Moniot M, Roux AL, Tournus C, Desbois-Nogard N, Le Coustumier A, Moquet O, Alanio A, Dromer F; French Mycoses Study Group. Bretagne S, et al. Microbiol Spectr. 2021 Oct 31;9(2):e0113821. doi: 10.1128/Spectrum.01138-21. Epub 2021 Oct 20. Microbiol Spectr. 2021. PMID: 34668768 Free PMC article.
  • Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study.
    Gangneux JP, Dannaoui E, Fekkar A, Luyt CE, Botterel F, De Prost N, Tadié JM, Reizine F, Houzé S, Timsit JF, Iriart X, Riu-Poulenc B, Sendid B, Nseir S, Persat F, Wallet F, Le Pape P, Canet E, Novara A, Manai M, Cateau E, Thille AW, Brun S, Cohen Y, Alanio A, Mégarbane B, Cornet M, Terzi N, Lamhaut L, Sabourin E, Desoubeaux G, Ehrmann S, Hennequin C, Voiriot G, Nevez G, Aubron C, Letscher-Bru V, Meziani F, Blaize M, Mayaux J, Monsel A, Boquel F, Robert-Gangneux F, Le Tulzo Y, Seguin P, Guegan H, Autier B, Lesouhaitier M, Pelletier R, Belaz S, Bonnal C, Berry A, Leroy J, François N, Richard JC, Paulus S, Argaud L, Dupont D, Menotti J, Morio F, Soulié M, Schwebel C, Garnaud C, Guitard J, Le Gal S, Quinio D, Morcet J, Laviolle B, Zahar JR, Bougnoux ME. Gangneux JP, et al. Lancet Respir Med. 2022 Feb;10(2):180-190. doi: 10.1016/S2213-2600(21)00442-2. Epub 2021 Nov 26. Lancet Respir Med. 2022. PMID: 34843666 Free PMC article.
  • COVID-19-Associated Pulmonary Aspergillosis (CAPA).
    Dimopoulos G, Almyroudi MP, Myrianthefs P, Rello J. Dimopoulos G, et al. J Intensive Med. 2021 Aug 7;1(2):71-80. doi: 10.1016/j.jointm.2021.07.001. eCollection 2021 Oct. J Intensive Med. 2021. PMID: 36785564 Free PMC article. Review.
  • COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment.
    Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, Cornely OA, S Perlin D, Lass-Flörl C, Hoenigl M. Arastehfar A, et al. J Fungi (Basel). 2020 Jun 24;6(2):91. doi: 10.3390/jof6020091. J Fungi (Basel). 2020. PMID: 32599813 Free PMC article. Review.
See all similar articles

Cited by

References

    1. Falcone M, Tiseo G, Giordano C, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021;76:1078–1084. - PMC - PubMed
    1. Falcone M, Suardi LR, Tiseo G, et al. Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study) JAC Antimicrob Resist. 2022;4:dlac064. - PMC - PubMed
    1. Falcone M, Tiseo G, Arcari G, et al. Spread of hypervirulent multidrug-resistant ST147 Klebsiella pneumoniae in patients with severe COVID-19: an observational study from Italy, 2020–21. J Antimicrob Chemother. 2022;77:1140–1145. - PMC - PubMed
    1. Antinori S, Galimberti L, Milazzo L, Ridolfo AL. Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia. Infez Med. 2020;28:29–36. - PubMed
    1. Egger M, Bussini L, Hoenigl M, Bartoletti M. Prevalence of COVID-19-associated pulmonary aspergillosis: critical review and conclusions. J Fungi (Basel) 2022;8:390. - PMC - PubMed

Grants and funding

This work was supported by Gilead that provided an unconditional support for data collection.

LinkOut - more resources